Design, Synthesis, and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents <i>In Vitro</i> and <i>In Vivo</i>
作者:Er-Jun Hao、Gong-Xin Li、Yu-Ru Liang、Ming-Sheng Xie、Dong-Chao Wang、Xiao-Han Jiang、Jia-Yi Cheng、Zhi-Xian Shi、Yang Wang、Hai-Ming Guo
DOI:10.1021/acs.jmedchem.0c01717
日期:2021.2.25
In the present work, 103 novel acyclic nucleosides were designed, synthesized, and evaluated for their anticancer activities in vitro and in vivo. The structure–activity relationship (SAR) studies revealed that most target compounds inhibited the growth of colon cancer cells in vitro, of which 3-(6-chloro-9H-purin-9-yl)dodecan-1-ol (9b) exhibited the most potent effect against the HCT-116 and SW480
在目前的工作中,设计、合成了 103 种新型无环核苷,并评估了它们的体外和体内抗癌活性。构效关系(SAR)研究表明,大多数目标化合物在体外均能抑制结肠癌细胞的生长,其中3-(6-氯-9 H -purin-9-yl)dodecan-1-ol ( 9b )对 HCT-116 和 SW480 细胞表现出最有效的作用,IC 50值分别为 0.89 和 1.15 μM。此外,所有( R )-构型的无环核苷衍生物与其( S )-对应物相比都表现出更有效的抗癌活性。机理研究表明,化合物9b通过线粒体膜去极化引发癌细胞系凋亡,并有效抑制集落形成。重要的是,化合物9b可抑制小鼠模型中 SW480 异种移植物的生长,且全身毒性较低。这些结果表明,无环核苷化合物可作为强效且有效的抗癌药物,而化合物9b可能作为一种有前途的先导化合物,在未来的抗癌药物发现中值得进一步关注。